GlassScriptPhysician profile
Vardges Vandian
NPI 1093755274
$4,223.12
in general payments reported to CMS, 2019-2025
25 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $800 · 2021: $1,210 · 2022: $259 · 2023: $453 · 2024: $365 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,010.56 | 2020-2025 | Qulipta, Ubrelvy |
| Ucb, INC. | $651.74 | 2019-2025 | Briviact |
| Teva Pharmaceuticals USA, INC. | $563.56 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $356.85 | 2019-2025 | Crexont, Rytary |
| Acadia Pharmaceuticals INC | $318.50 | 2019-2021 | |
| Sk Life Science, INC. | $201.17 | 2023-2025 | Xcopri |
| Biohaven Pharmaceuticals, INC. | $161.84 | 2020-2021 | |
| Lilly USA, LLC | $138.35 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $129.93 | 2020-2021 | |
| Acorda Therapeutics, INC | $129.45 | 2019-2021 | |
| Biogen, INC. | $102.59 | 2019-2021 | |
| Argenx US, INC. | $73.74 | 2022-2024 | Vyvgart Hytrulo |
| Almatica Pharma LLC | $62.01 | 2021 | |
| Neurelis, INC. | $59.05 | 2021 | |
| Pfizer INC. | $37.83 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.62 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $35.88 | 2019 | |
| Allergan, INC. | $29.40 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.93 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $19.14 | 2021 | |
| Neurocrine Biosciences, INC. | $17.52 | 2019 | |
| Bausch Health US, LLC | $17.25 | 2019 | |
| Ge Healthcare | $16.17 | 2019 | |
| Impel Pharmaceuticals INC. | $13.20 | 2023 | Trudhesa |
| Horizon Therapeutics Plc | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vardges Vandian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.